已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial

医学 内科学 脂肪性肝炎 内分泌学 相(物质) 临床试验 非酒精性脂肪性肝炎 胃肠病学 糖尿病 疾病 代谢综合征
作者
Rohit Seth Loomba,Stanley Wang,Dimple Desai,Daniel Santillano,Kathryn Jean Lucas,Guy Neff,Antonio Carlos Bianco,Eveline Bruinstroop,Yan Su,Hardean E. Achneck,Kha Le,Megan Fitzgerald,Min Wu,Tse-I Lin,Sushmita M. Chanda,Lawrence Mitchell Blatt,Christos Socrates Mantzoros
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:11 (11): 984-996
标识
DOI:10.1016/s2468-1253(26)00154-8
摘要

BACKGROUND: Thyroid hormone receptor β (THR-β) agonists reduce atherogenic lipids, hepatic fat, and improve histology in metabolic dysfunction-associated steatohepatitis (MASH). The phase 2a HERALD study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of the selective and potent THR-β agonist ALG-055009 in non-cirrhotic adult patients with presumed MASH. METHODS: and a diagnosis of presumed non-alcoholic steatohepatitis (NASH) or MASH with F1-F3 liver fibrosis were randomly assigned to receive oral ALG-055009 (0·3 mg, 0·5 mg, 0·7 mg, or 0·9 mg) or placebo once daily for 12 weeks. Enrolment in the 0·9 mg group was limited to participants with bodyweight of more than 85 kg. The primary endpoint was percentage relative change from baseline in liver fat by MRI-proton density fat fraction (MRI-PDFF) at week 12 in the MRI-PDFF analysis population. The trial is registered at ClinicalTrials.gov, NCT06342947, and is now completed. FINDINGS: 102 participants (39 [38%] males and 63 [62%] females) were randomly assigned to receive ALG-055009 0·3 mg (n=20), ALG-055009 0·5 mg (n=22), ALG-055009 0·7 mg (n=20), ALG-055009 0·9 mg (n=18), or placebo (n=22); five participants (two in the 0·3 mg group, one in the 0·5 mg group, one in the 0·9 mg group, and one in the placebo group) did not have baseline and week 12 MRI-PDFF data and were thus not included in the analysis of the primary endpoint. Least-squares mean relative change in liver fat at week 12 was -6·9% (95% CI -19·2 to 5·3) with 0·3 mg ALG-055009, -11·2% (-22·9 to 0·4) with 0·5 mg ALG-055009, -25·9% (-37·7 to -14·1) with 0·7 mg ALG-055009, -24·3% (-37·9 to -10·6) with 0·9 mg ALG-055009, and 7·3% (-4·0 to 18·6) with placebo. Placebo-adjusted least-squares mean relative changes in liver fat at week 12 were therefore -14·3% (95% CI -29·6 to 1·0; p=0·067) for 0·3 mg ALG-055009, -18·5% (-33·3 to -3·8; p=0·014) for 0·5 mg ALG-055009, -33·2% (-48·1 to -18·3; p<0·0001) for 0·7 mg ALG-055009, and -31·6% (-47·4 to -15·8; p=0·0001) for 0·9 mg ALG-055009. Treatment-emergent adverse events occurred in 13 (65%) participants receiving 0·3 mg ALG-055009, ten (45%) receiving 0·5 mg ALG-055009, 13 (65%) receiving 0·7 mg ALG-055009, 11 (61%) receiving 0·9 mg ALG-055009, and in 16 (73%) receiving placebo. Most treatment-emergent adverse events were mild or moderate, with the most common being diarrhoea (ten [10%]), fatigue (six [6%]), and constipation (five [5%]). One serious adverse event occurred in the placebo group, and no deaths occurred. Gastrointestinal treatment-emergent adverse event rates for ALG-055009 were similar to placebo, and no clinically meaningful changes in laboratory tests, electrocardiogram, vital signs, physical exams, or thyroid function were observed. INTERPRETATION: Statistically significant reductions in liver fat with ALG-055009 and no relevant safety issues suggest that ALG-055009 could offer a promising treatment approach for patients with MASH. Results support evaluating extended ALG-055009 dosing on liver histology in participants with MASH. FUNDING: Aligos Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
白华苍松发布了新的文献求助10
刚刚
搜集达人的应助被羽七采纳,获得10
刚刚
偏偏星星完成签到 ,获得积分10
刚刚
科研通AI6.3的应助被stevenli采纳,获得10
1秒前
CodeCraft的应助被李博宇采纳,获得10
2秒前
3秒前
阿娴完成签到 ,获得积分10
3秒前
幸运鹅完成签到 ,获得积分10
4秒前
5秒前
糖心完成签到,获得积分10
5秒前
6秒前
脑洞疼的应助被richardhipower采纳,获得10
6秒前
6秒前
Abandon1完成签到 ,获得积分10
7秒前
8秒前
Orange的应助被硫酸盐采纳,获得10
9秒前
FashionBoy的应助被listen采纳,获得10
9秒前
xiankanyun发布了新的文献求助10
10秒前
12秒前
情怀的应助被李洪杰采纳,获得10
12秒前
开心香岚发布了新的文献求助10
13秒前
美满的诗蕾完成签到,获得积分10
14秒前
海洋完成签到 ,获得积分10
14秒前
丘比特的应助被清脆的静曼采纳,获得10
14秒前
沙漏的回忆完成签到 ,获得积分10
15秒前
15秒前
Clay完成签到 ,获得积分10
15秒前
慕青的应助被richardhipower采纳,获得10
17秒前
yangpeiyao完成签到,获得积分10
17秒前
tao_ht完成签到,获得积分20
18秒前
开心香岚完成签到,获得积分10
18秒前
18秒前
gfydsl发布了新的文献求助20
19秒前
小豆包发布了新的文献求助10
19秒前
19秒前
虚心发布了新的文献求助10
20秒前
结实的鸵鸟完成签到 ,获得积分10
20秒前
fdwonder完成签到,获得积分0
20秒前
Tom完成签到,获得积分10
20秒前
落寞绝音完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699